OKYO Pharma chairman lifts stake to 20.55%

OKYO Pharma Limited reported that Chairman Gabriele Cerrone, through Panetta Partners Ltd, acquired 22,500 ordinary shares at $1.45 per share.

Accepted by SEC EDGAR 07/22/2026 - 12:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Limited reported that Chairman Gabriele Cerrone, through Panetta Partners Ltd, acquired 22,500 ordinary shares at $1.45 per share. Following this purchase, he beneficially holds 10,873,916 ordinary shares, representing 20.55% of the company’s issued share capital.

OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases. The company plans a global Phase 3 pivotal trial of urcosimod in the second half of this year, targeting enrollment of approximately 111 patients on a single-dose regimen.

Key Figures

Recent share purchase: 22,500 ordinary shares Purchase price: $1.45 per share Chairman total holdings: 10,873,916 ordinary shares +2 more

5 metrics

Recent share purchase 22,500 ordinary shares Shares acquired by Chairman Gabriele Cerrone through Panetta Partners Ltd

Purchase price $1.45 per share Price paid for the 22,500 ordinary shares acquired by the chairman-associated entity

Chairman total holdings 10,873,916 ordinary shares Total ordinary shares beneficially held by the Chairman after the purchase

Ownership percentage 20.55% of issued share capital Chairman’s beneficial ownership of OKYO Pharma after the transaction

Planned trial enrollment approximately 111 patients Target enrollment for the planned global Phase 3 urcosimod trial in NCP

Key Terms

neuropathic corneal pain (NCP), anterior segment eye diseases, Phase 3 pivotal clinical trial, issued share capital, +1 more

5 terms

neuropathic corneal pain (NCP) medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

anterior segment eye diseases medical

"and anterior segment eye diseases, with ordinary shares listed"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

issued share capital financial

"bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital."

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

beneficial interest financial

"Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings"

Beneficial interest is the right to receive the economic benefits of an asset—such as dividends, interest, or sale proceeds—without necessarily holding legal title to it. For investors this matters because it determines who actually gains from an investment or trust, much like renting an apartment where the tenant enjoys living there and paying bills while the landlord holds the deed; understanding who has the beneficial interest affects income rights, voting influence, and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did OKYO Pharma (OKYO) disclose for its chairman?

OKYO Pharma disclosed that Chairman Gabriele Cerrone, via Panetta Partners Ltd, bought 22,500 ordinary shares at $1.45 per share. This transaction increased his beneficial holdings to 10,873,916 shares, giving him 20.55% of the company’s issued share capital.

What percentage of OKYO Pharma (OKYO) does the chairman now own?

After the latest purchase, Chairman Gabriele Cerrone beneficially owns 20.55% of OKYO Pharma’s issued share capital. This reflects holdings of 10,873,916 ordinary shares, acquired directly and through Panetta Partners Ltd, an entity in which he has a beneficial interest.

At what price were the newly purchased OKYO Pharma (OKYO) shares acquired?

The new OKYO Pharma shares were bought at $1.45 per ordinary share. Chairman Gabriele Cerrone, acting through Panetta Partners Ltd, purchased 22,500 ordinary shares at this price, contributing to his total beneficial holding of 10,873,916 shares.

What is OKYO Pharma (OKYO) developing as its lead program?

OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. Its lead candidate, urcosimod, is being advanced toward a pivotal Phase 3 trial targeting patients with NCP.

What are the key details of OKYO Pharma’s (OKYO) planned Phase 3 urcosimod trial?

OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients. The study will evaluate a single-dose regimen of urcosimod for the treatment of neuropathic corneal pain (NCP).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 22, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 22, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 22, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chairman

London and New York, NY, July 22, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 5.8 KB
• EX-99 GRAPHIC 9.3 KB